New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway
about
Skp2: a novel potential therapeutic target for prostate cancerProstate cancer stem cells: the role of androgen and estrogen receptorsAndrogen receptor on the move: boarding the microtubule expressway to the nucleusFrom bench to bedside: immunotherapy for prostate cancerMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progressionCelecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma.Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cellsAndrogen receptor and its splice variants in prostate cancerDose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding.Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerEnzalutamide for patients with metastatic castration-resistant prostate cancerMaximal testosterone suppression in prostate cancer--free vs total testosteroneCSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.Establishing prostate cancer patient derived xenografts: lessons learned from older studiesResponse of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.Genome-wide analysis of androgen receptor binding sites in prostate cancer cells.Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancerMUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.Local endocrine, paracrine and redox signaling networks impact estrogen and androgen crosstalk in the prostate cancer microenvironmentCUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo EfficacyPatient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.Advances in androgen receptor targeted therapy for prostate cancerThe HIF/PHF8/AR axis promotes prostate cancer progression.Maximizing the quantitative accuracy and reproducibility of Förster resonance energy transfer measurement for screening by high throughput widefield microscopy.Beyond castration-defining future directions in the hormonal treatment of prostate cancer.Overcoming docetaxel resistance in prostate cancer: a perspective review.Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.The hurdle of antiandrogen drug resistance: drug design strategies.AR function in promoting metastatic prostate cancerTherapeutic modulation of prostate cancer metastasis.Evolution of androgen receptor targeted therapy for advanced prostate cancer.Chemical castration and anti-androgens induce differential gene expression in prostate cancer.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
P2860
Q24625558-55C839FC-E9AF-4288-B62D-366E4ADFA101Q26778415-F9E42274-EC41-4B56-9324-905FA0B33298Q26862560-16851BFC-4D35-4D6F-A104-4FC3BF18CE7FQ26864390-A10BA9C3-7EC5-41E9-B82F-15FED5CCB44DQ27024775-3A8CB254-1E0A-41B9-B247-1D0B379FB978Q30409623-97038D75-AE6B-4807-BA18-0D61252687EAQ30513836-D6D7DCD8-D2EC-471D-977E-6BDCA6C197C3Q30521133-0767E6AF-9E21-468C-B88F-66F2309C6CF4Q30554439-185A0958-827D-4CD8-B4BA-D3BB51F45071Q33943265-FDE79865-8404-4C36-907A-3BF2EE78450DQ33988851-0CAEE7F1-8B64-4B78-B501-20AC0FB178DEQ34199684-24B9D4C6-42EA-44E1-B382-7499BD11E68FQ34360076-EB2D329E-BE3D-40E7-8BAE-F030DDC697F2Q34416771-5B8A392A-FA2F-4AA4-9322-F7F11E0CE97BQ34475171-2EE42C84-4D4C-4FA7-B67F-057175719207Q35096022-88E29E98-B026-445C-A673-438C40F2536DQ35178381-9D6E75BB-ED2F-49F9-8D58-84A5B4C14852Q35556598-DADFE5F9-3160-4EE9-AC47-4B21B847D083Q35603263-F59297EF-04CF-4314-A1F7-78871BFA3A43Q35758864-2DA70981-B1E6-4038-BB35-3069CF216B90Q35967139-148CD800-425E-44FE-9341-DE533E921F76Q36146986-142F9778-F669-4711-8BB3-51A834CD4B4FQ36303184-6B2D142A-8013-4FAB-B1F7-033D9F75A155Q36383057-B36896F3-CC5E-4F66-AE26-179EBFCB4682Q36817810-1063EE33-BD31-4209-B236-E676B02EADAFQ36978557-6C410A2C-5B3F-43C9-B0AA-CEB5F669654AQ37153672-C231FBEC-338A-4C65-8343-00392FC3F7DEQ37323018-8E3511C6-3812-4753-9451-FD9244D40345Q37337217-C8A18700-965A-4E00-8CA7-C64DDA3679E6Q37525781-C0BE561A-5D2B-426D-B161-9CD52F19A55EQ37565027-D97D121E-C9B9-46D0-BAC9-DD94D9D9A0D5Q37962393-D9B66BA9-5159-4991-AB77-6FBEE8EF07DBQ38057235-D20417AC-D05A-41EF-B442-8ED16A2E3917Q38131735-CFC63B4C-A321-412F-A500-A0596B0ADD60Q38160927-02640080-3D33-4748-93A7-52E7929F612DQ38178555-17C74FC1-C173-41ED-8DA8-30905DE7F09FQ38182140-25AA72FB-70AA-4ED2-885B-5B35162308C9Q38212716-BE5D2851-70D0-414E-ACCD-7787C5206451Q38326753-91B8992B-6F39-4F60-BF83-4BCFFFE42ECEQ38374417-67BCCC7D-E2C7-4C5B-8B65-F02F42F427A4
P2860
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
New strategies in metastatic p ...... gen receptor signaling pathway
@ast
New strategies in metastatic p ...... gen receptor signaling pathway
@en
New strategies in metastatic p ...... gen receptor signaling pathway
@nl
type
label
New strategies in metastatic p ...... gen receptor signaling pathway
@ast
New strategies in metastatic p ...... gen receptor signaling pathway
@en
New strategies in metastatic p ...... gen receptor signaling pathway
@nl
prefLabel
New strategies in metastatic p ...... gen receptor signaling pathway
@ast
New strategies in metastatic p ...... gen receptor signaling pathway
@en
New strategies in metastatic p ...... gen receptor signaling pathway
@nl
P2860
P1476
New strategies in metastatic p ...... gen receptor signaling pathway
@en
P2093
Johann S de Bono
Juliet Richards
P2860
P304
P356
10.1158/1078-0432.CCR-10-0567
P407
P577
2011-03-03T00:00:00Z